Ex-Ax­o­vant COO Mar­i­on Mc­Court lands at Re­gen­eron; GT Bio­phar­ma el­e­vates Shawn Cross to CEO in ex­ec reshuf­fle

→ While our eyes were fixed on CEO David Hung’s de­par­ture from strug­gling Ax­o­vant, COO Mar­i­on Mc­Court al­so qui­et­ly jumped ship — to Re­gen­eron $REGN. The com­pa­ny an­nounced Mon­day (the same day Mc­Court’s res­ig­na­tion from Ax­o­vant was made pub­lic) that it has ap­point­ed her as SVP and head of com­mer­cial. The ap­point­ment filled a va­can­cy left by Robert Ter­i­fay, who re­signed last month in the mid­dle of a med­ical leave and plans to re­tire in Ju­ly. A sea­soned ex­ec with foot­prints at As­traZeneca, Am­gen and Medi­va­tion, Mc­Court will lead the com­mer­cial­iza­tion for both ap­proved med­i­cines and de­vel­op-stage pipeline.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.